Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2022-07-13 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
关于富马酸丙酚替诺福韦片拟中选全国药品集中采购的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Anhui Anke Bioengineering (Group) Co., Ltd. regarding the proposed selection of a pharmaceutical product (Fumarate Propofol Tenofovir Tablets) in a national centralized drug procurement. It includes details about the product, pricing, supply regions, and the potential impact on the company. The document is short (1164 characters) and serves as an announcement of a business event related to procurement and sales, not a financial report or detailed regulatory filing. It does not contain financial statements, audit information, or management discussion. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about business operations and procurement results that do not fit other specific categories.
2022-07-13 Chinese
关于子公司员工股权激励方案进展暨完成工商变更登记的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Anhui Anke Biological Engineering (Group) Co., Ltd. regarding the progress of an employee equity incentive plan for its subsidiary and the completion of related industrial and commercial registration changes. It details the transfer of part of the subsidiary's equity to management as part of the incentive plan, changes in shareholding percentages, and updated registration information. The document is a formal announcement of a corporate action related to equity incentive and shareholding structure changes, not a financial report, earnings release, or regulatory certification. It does not contain financial statements or detailed financial analysis but rather reports on a corporate governance and capital structure update. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2022-07-04 Chinese
关于回购公司股份进展情况的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of the company's share repurchase program. It details the number of shares repurchased, the price range, compliance with regulatory rules, and the timeline of the repurchase plan. It does not contain financial statements or comprehensive financial data but rather updates on the share buyback activity. The document length is short (1451 characters) and focuses on share repurchase progress, which fits the category of Transaction in Own Shares (POS).
2022-07-04 Chinese
安徽天禾律师事务所关于安徽安科生物工程（集团）股份有限公司2022年第一次临时股东大会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, and voting procedures of the 2022 first extraordinary general meeting (临时股东大会) of Anhui Anke Bioengineering (Group) Co., Ltd. It details the legality and compliance of the meeting process, attendance qualifications, voting procedures, and the validity of resolutions passed. It does not contain financial statements or performance data, nor is it a report or announcement of financial results. It is a legal opinion related to a shareholder meeting, which is a specialized document type. Given the content focuses on the shareholder meeting and legal compliance, it aligns best with Declaration of Voting Results & Voting Rights Announcements (DVA), as it includes detailed voting results and legal validation of the meeting and resolutions. The document length is under 5,000 characters, but it is not merely an announcement of a report; it is a legal opinion on the meeting and voting results. Therefore, the most appropriate classification is DVA with high confidence.
2022-06-16 Chinese
关于第七届董事会第二十一次会议决议的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resolution of the 21st meeting of the 7th Board of Directors of Anhui Anke Biotechnology (Group) Co., Ltd. It details the appointment of a new company vice president, including the voting results and the appointee's resume. There is no financial data, no mention of annual or quarterly reports, no audit information, and no regulatory filings or legal proceedings. The content focuses on board/management changes, specifically the appointment of a senior executive. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS.
2022-06-16 Chinese
2022年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the resolutions passed at the 2022 first extraordinary general meeting (临时股东大会) of Anhui Anke Biological Engineering (Group) Co., Ltd. It details the meeting date, attendance, voting results, and legal opinions confirming the validity of the meeting and resolutions. There is no financial data or detailed report content, only the official voting results and meeting summary. The document length is short (1775 characters) and it serves as a formal announcement of voting results from a shareholder meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-06-16 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.